Clinical Trial Update: A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study) [Phase 2]

View source ↗

Summary

Phase 2 study results evaluate canakinumab for preventing acute gout flares in patients starting allopurinol, with a long-term extension assessing ongoing effic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gout | Phase 2 | Status: COMPLETED | Results posted: 2011-05-06